Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

Christopoulos P, Engel-Riedel W, Grohé C, Kropf-Sanchen C, von Pawel J, Gütz S, Kollmeier J, Eberhardt W, Ukena D, Baum V, Nimmrich I, Sieder C, Schnabel PA, Serke M, Thomas M.

Ann Oncol. 2017 Aug 1;28(8):1898-1902. doi: 10.1093/annonc/mdx268.


Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, Kubista E, Baumgärtner AK, Beckmann MW, May C, Nimmrich I, Harbeck N.

Breast. 2012 Feb;21(1):27-33. doi: 10.1016/j.breast.2011.07.006. Epub 2011 Sep 8.


Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R.

J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18.


DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.


DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Eur J Cancer. 2007 Jul;43(11):1679-86. Epub 2007 Jun 29.


DNA methylation markers - an opportunity to further individualize therapy in breast cancer?

Maier S, Lesche R, Nimmrich I, Eckhardt F, Dahlstroem C, Plum A.

Per Med. 2005 Nov;2(4):339-347. doi: 10.2217/17410541.2.4.339.


Differential DNA methylation of gene promoters in small B-cell lymphomas.

Guo J, Burger M, Nimmrich I, Maier S, Becker E, Genc B, Duff D, Rahmatpanah F, Chitma-Matsiga R, Shi H, Berlin K, Huang TH, Caldwell CW.

Am J Clin Pathol. 2005 Sep;124(3):430-9.


Methylation discriminators in NSCLC identified by a microarray based approach.

Field JK, Liloglou T, Warrak S, Burger M, Becker E, Berlin K, Nimmrich I, Maier S.

Int J Oncol. 2005 Jul;27(1):105-11.


Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.

Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA.

Cancer Res. 2005 May 15;65(10):4101-17.


Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis.

Scholz C, Nimmrich I, Burger M, Becker E, Dörken B, Ludwig WD, Maier S.

Ann Hematol. 2005 Apr;84(4):236-44. Epub 2004 Nov 6.


The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas.

Yang H, Chen CM, Yan P, Huang TH, Shi H, Burger M, Nimmrich I, Maier S, Berlin K, Caldwell CW.

Clin Cancer Res. 2003 Sep 15;9(11):4034-42.


Oligonucleotide-based microarray for DNA methylation analysis: principles and applications.

Shi H, Maier S, Nimmrich I, Yan PS, Caldwell CW, Olek A, Huang TH.

J Cell Biochem. 2003 Jan 1;88(1):138-43. Review.


Epigenomics: genome-wide study of methylation phenomena.

Novik KL, Nimmrich I, Genc B, Maier S, Piepenbrock C, Olek A, Beck S.

Curr Issues Mol Biol. 2002 Oct;4(4):111-28. Review.


Murine Nr4a1 and Herpud1 are up-regulated by Wnt-1, but the homologous human genes are independent from beta-catenin activation.

Chtarbova S, Nimmrich I, Erdmann S, Herter P, Renner M, Kitajewski J, Müller O.

Biochem J. 2002 Nov 1;367(Pt 3):723-8.


The novel ependymin related gene UCC1 is highly expressed in colorectal tumor cells.

Nimmrich I, Erdmann S, Melchers U, Chtarbova S, Finke U, Hentsch S, Hoffmann I, Oertel M, Hoffmann W, Müller O.

Cancer Lett. 2001 Apr 10;165(1):71-9.


Seven genes that are differentially transcribed in colorectal tumor cell lines.

Nimmrich I, Erdmann S, Melchers U, Finke U, Hentsch S, Moyer MP, Hoffmann I, Müller O.

Cancer Lett. 2000 Nov 10;160(1):37-43.


A beta-catenin mutation in a sporadic colorectal tumor of the RER phenotype and absence of beta-catenin germline mutations in FAP patients.

Müller O, Nimmrich I, Finke U, Friedl W, Hoffmann I.

Genes Chromosomes Cancer. 1998 May;22(1):37-41.


Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP.

Nimmrich I, Friedl W, Kruse R, Pietsch S, Hentsch S, Deuter R, Winde G, Müller O.

Hum Genet. 1997 Sep;100(3-4):345-9.


Supplemental Content

Loading ...
Support Center